Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763009 · ClinicalTrials.gov registry record · Phase 4
Persantine: Variation in Response Trial
A Phase 4 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00763009 is a Phase 4 study that was terminated before completion, run by UConn Health. The registered enrollment target is 8 participants.
The verdict
NCT00763009, a Phase 4 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
Interventions
- DRUG dipyridamole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763009
The ClinicalTrials.gov registry entry for NCT00763009 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dipyridamole is the first listed.
NCT00763009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00763009 about?
NCT00763009 is a clinical study titled "Persantine: Variation in Response Trial". The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a ...
What is the current status of trial NCT00763009?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2002-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00763009?
The interventions under investigation include: dipyridamole (DRUG).
Who is sponsoring clinical trial NCT00763009?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.